| __timestamp | ADMA Biologics, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 1656170000 |
| Thursday, January 1, 2015 | 4311461 | 2003565000 |
| Friday, January 1, 2016 | 6360761 | 2137539000 |
| Sunday, January 1, 2017 | 29164321 | 2166062000 |
| Monday, January 1, 2018 | 42194635 | 2437164000 |
| Tuesday, January 1, 2019 | 39504238 | 2757459000 |
| Wednesday, January 1, 2020 | 61291426 | 3084873000 |
| Friday, January 1, 2021 | 79769341 | 2970522000 |
| Saturday, January 1, 2022 | 118814535 | 3832437000 |
| Sunday, January 1, 2023 | 169273000 | 4269276000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, understanding cost structures is crucial. This chart highlights the cost of revenue trends for Grifols, S.A. and ADMA Biologics, Inc. from 2014 to 2023. Grifols, a leader in plasma-derived therapies, consistently shows a robust cost of revenue, peaking at approximately $4.3 billion in 2023, a 158% increase from 2014. Meanwhile, ADMA Biologics, a smaller player, has seen its cost of revenue skyrocket by over 4,400%, reaching around $169 million in 2023. This dramatic rise reflects ADMA's aggressive expansion and scaling efforts. The data underscores the contrasting scales and growth trajectories of these companies, offering insights into their operational strategies. As the biotech industry continues to grow, monitoring these trends provides valuable foresight into future market dynamics.
Cost of Revenue Comparison: Novo Nordisk A/S vs Grifols, S.A.
Regeneron Pharmaceuticals, Inc. vs Grifols, S.A.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: BeiGene, Ltd. and Grifols, S.A.
Viatris Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and ADMA Biologics, Inc.'s Expenses
Walgreens Boots Alliance, Inc. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Halozyme Therapeutics, Inc. vs Grifols, S.A.: Efficiency in Cost of Revenue Explored
Grifols, S.A. vs Cytokinetics, Incorporated: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Grifols, S.A. and Mesoblast Limited's Expenses
Comparing Cost of Revenue Efficiency: Grifols, S.A. vs Iovance Biotherapeutics, Inc.
Cost of Revenue: Key Insights for Grifols, S.A. and Xencor, Inc.
Comparing Cost of Revenue Efficiency: ADMA Biologics, Inc. vs MiMedx Group, Inc.